Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment

Sandén, Emma LU ; Khazaei, Somayeh LU ; Tryggvadottir, Helga LU ; Borgquist, Signe LU ; Isaksson, Karolin LU ; Jirström, Karin LU orcid and Jernström, Helena LU (2020) In Virchows Archiv 477(2). p.317-320
Abstract

Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005–2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were... (More)

Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005–2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Gene protein assay, HER2, Immunohistochemistry, In situ hybridization, Tissue microarray, Whole tissue section
in
Virchows Archiv
volume
477
issue
2
pages
4 pages
publisher
Springer
external identifiers
  • pmid:32080761
  • scopus:85079822812
ISSN
0945-6317
DOI
10.1007/s00428-020-02768-x
language
English
LU publication?
yes
id
ac6c5c23-93b6-49d7-92c0-b5cbee31f8fc
date added to LUP
2020-03-18 13:54:15
date last changed
2024-10-02 22:29:15
@article{ac6c5c23-93b6-49d7-92c0-b5cbee31f8fc,
  abstract     = {{<p>Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005–2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.</p>}},
  author       = {{Sandén, Emma and Khazaei, Somayeh and Tryggvadottir, Helga and Borgquist, Signe and Isaksson, Karolin and Jirström, Karin and Jernström, Helena}},
  issn         = {{0945-6317}},
  keywords     = {{Gene protein assay; HER2; Immunohistochemistry; In situ hybridization; Tissue microarray; Whole tissue section}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{317--320}},
  publisher    = {{Springer}},
  series       = {{Virchows Archiv}},
  title        = {{Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment}},
  url          = {{http://dx.doi.org/10.1007/s00428-020-02768-x}},
  doi          = {{10.1007/s00428-020-02768-x}},
  volume       = {{477}},
  year         = {{2020}},
}